<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161872</url>
  </required_header>
  <id_info>
    <org_study_id>P-20180016368</org_study_id>
    <nct_id>NCT04161872</nct_id>
  </id_info>
  <brief_title>Nutraceutical on Hyperuricemia</brief_title>
  <official_title>Evaluation of the Effects of a Supplement Composed by Quercetin, Rutin, Bromelain and L-carnosine in Patients With Hyperuricemia, a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study will be to evaluate if a nutraceutical containing quercetin, rutin,
      bromelain and L-carnosine (Uricemin®) can reduce uric acid levels in subjects with values
      between ≥ 6 and &lt; 7 mg/dl after 3 months of therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study will be to evaluate if a nutraceutical containing quercetin, rutin,
      bromelain and L-carnosine (Uricemin®) can reduce uric acid levels in subjects with values
      between ≥ 6 and &lt; 7 mg/dl after 3 months of therapy.

      Patients will be randomized to Uricemin® or placebo for three months. We will evaluate body
      weight, fasting plasma glucose (FPG), lipid profile, uricemia (UA), high-sensitivity
      C-reactive protein (Hs-CRP) at baseline and after 3 months since the study start. Treatment
      tolerability will be assessed evaluating transaminases, and creatinine, and all adverse
      events will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of Hyperuricemia</measure>
    <time_frame>3 months</time_frame>
    <description>Uric acid levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Uricemin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uricemin</intervention_name>
    <description>Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine</description>
    <arm_group_label>Uricemin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with uric acid levels between ≥ 6 and &lt; 7 mg/dl

          -  Patients not taking hypouricemic agents (both pharmaceuticals or nutraceutical agents)

        Exclusion Criteria:

          -  Patients with previous gout attack

          -  Patients with impaired hepatic function

          -  Patient with impaired renal function

          -  Patients with gastrointestinal disorders

          -  Patients with current or previous evidence of ischemic heart disease, heart failure,
             or stroke

          -  Patients with weight change of &gt; 3 Kg during the preceding 3 months

          -  Patients with history of malignancy, and significant neurological or psychiatric
             disturbances, including alcohol or drug abuse.

          -  Patients taking (within the previous 3 months) hypouricemic agents, laxatives,
             beta-agonists (other than inhalers), cyproheptadine, antidepressants,
             antiserotoninergics, phenothiazines, barbiturates, oral corticosteroids, and
             antipsychotics

          -  Women who were pregnant or breastfeeding or of childbearing potential and not taking
             adequate contraceptive precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD, FESC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

